Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGC · Real-Time Price · USD
4.920
-0.010 (-0.20%)
Dec 20, 2024, 4:00 PM EST - Market closed
RGC Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Selling, General & Admin | 3.78 | 3.78 | 4.8 | 5.11 | 0.94 | 0.43 | |
| Research & Development | 0.95 | 0.95 | 1.47 | 2.51 | 0.44 | 0.39 | |
| Operating Expenses | 4.74 | 4.74 | 6.27 | 7.62 | 1.38 | 0.81 | |
| Operating Income | -4.74 | -4.74 | -6.27 | -7.62 | -1.38 | -0.81 | |
| EBT Excluding Unusual Items | -4.74 | -4.74 | -6.27 | -7.62 | -1.38 | -0.81 | |
| Other Unusual Items | 0.37 | 0.37 | 0.21 | 0.02 | 0.03 | - | |
| Pretax Income | -4.36 | -4.36 | -6.06 | -7.59 | -1.35 | -0.81 | |
| Earnings From Continuing Operations | -4.36 | -4.36 | -6.06 | -7.59 | -1.35 | -0.81 | |
| Minority Interest in Earnings | 0.06 | 0.06 | 0.19 | 0.15 | - | - | |
| Net Income | -4.3 | -4.3 | -5.87 | -7.45 | -1.35 | -0.81 | |
| Net Income to Common | -4.3 | -4.3 | -5.87 | -7.45 | -1.35 | -0.81 | |
| Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 10 | 10 | |
| Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 10 | 10 | |
| Shares Change (YoY) | - | - | 1.62% | 28.06% | - | - | |
| EPS (Basic) | -0.33 | -0.33 | -0.45 | -0.58 | -0.13 | -0.08 | |
| EPS (Diluted) | -0.33 | -0.33 | -0.45 | -0.58 | -0.13 | -0.08 | |
| Free Cash Flow | -4.01 | -4.01 | -4.99 | -6.05 | -0.77 | -0.84 | |
| Free Cash Flow Per Share | -0.31 | -0.31 | -0.38 | -0.47 | -0.08 | -0.08 | |
| EBITDA | -4.43 | -4.43 | -5.98 | -7.47 | -1.35 | -0.8 | |
| D&A For EBITDA | 0.31 | 0.31 | 0.29 | 0.15 | 0.03 | 0.01 | |
| EBIT | -4.74 | -4.74 | -6.27 | -7.62 | -1.38 | -0.81 | |
| Advertising Expenses | 1 | 1 | 0.03 | 0.03 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.